Date: 2017-12-20
Type of information: Restructuring
Compound:
Company: TiGenix (Belgium)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement:
Action mechanism:
Disease:
Details:
- • On December 20, 2017, TiGenix announced that the company plans to focus its resources and capabilities on its eASC platform technology and its product candidates Cx601 and Cx611.
- This decision follows the recent positive CHMP opinion for Cx601 to treat complex perianal fistulas in Crohn's disease, which is a further step in making this product commercially available in Europe and highlights the potential of using allogeneic adipose-derived stem cells in the treatment of inflammatory conditions associated with immune-mediated diseases.
Financial terms:
Latest news:
Is general: Yes
